Journal of Affective Disorders
December 1, 2019
Mu-Hong Chen, Wei-Chen Lin, Pei-Chi Tu et al.
Increasing evidence suggests that infusion of a subanesthetic dose of ketamine exerts antidepressant and antisuicidal effects in patients with treatment-resistant depression (TRD). In this investigation, we used the resting functional connectivity magnetic resonance imaging (fcMRI) to determine the effects of ketamine on the functional connectivity (FC) of prefrontal cortex (PFC)-related...
Contemporary Clinical Trials Communications
December 1, 2019
Brittany O'Brien, Charles E. Green, Rayan K. Al Jurdi et al.
10 citations
More than eleven million U.S. Veterans are at least 65 years of age, an age group of which almost 20% suffers from clinically significant depressive symptoms. Available pharmacological treatments are suboptimal for patients, including veterans, with late-life depression. Ketamine has emerged as a potentially promising rapid-acting therapy for treatment-resistant depression (TRD). However, few...
BMC Psychiatry
November 29, 2019
Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jeanine Kamphuis et al.
There is an urgent need to develop additional treatment strategies for patients with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of intravenous (IV) ketamine as a racemic mixture have been shown repeatedly in this population, but there is still a paucity of data on the efficacy and safety of (a) different routes of administration, and (b) ketamine's...
Journal of Affective Disorders
November 14, 2019
Fernanda S. Correia-Melo, Gustavo C. Leal, Flávia Vieira et al.
188 citations
BACKGROUND Ketamine and its enantiomers have recently been highlighted as one of the most effective therapeutic options in refractory depression. However, racemic ketamine and esketamine have not been directly compared. The aim of this study is to assess the efficacy and safety of esketamine compared to ketamine in patients with treatment-resistant depression (TRD). METHODS This is a...
November 2, 2019
The algorithm for depressed inpatients with melancholia starts with considering whether there is an urgent indication for ECT. Imminent risk of suicide, catatonia, inadequate oral intake, and a past history of good response to ECT may be indications for ECT. Remission rates of 75% have been reported with ECT. If the patient has these indications but refuses or is intolerant of ECT, consider an...
The Brown University Child & Adolescent Psychopharmacology Update
November 1, 2019
The recent approval of esketamine (Spravato) by the Food and Drug Administration (FDA) has raised many questions for psychiatrists who treat major depression, and even bigger questions for child psychiatrists. It's not approved for pediatric use by the FDA, but that doesn't mean it can't be prescribed off‐label.
Psychiatry Research
November 1, 2019
Jun Dong, S. Min, H. Qiu et al.
26 citations
This study aimed to investigate the efficacy and safety of intermittent low-dose ketamine on improving the efficacy of ECT. Patients diagnosed with Major Depressive Disorder (MDD) (n = 134) were randomized into 3 groups: routine ECT group (group E, n = 45); repeated ketamine-assisted ECT group (group RK, n = 43), and intermittent ketamine-assisted ECT group (group IK, n = 46). Patients in group...
Alcoholism & Drug Abuse Weekly
October 7, 2019
Alison Knopf
Like its predecessor intravenous ketamine, an anesthetic that has been used off‐label to treat depression, esketamine has shown great promise in treating a disease that can destroy quality of life and lead to suicide. The Food and Drug Administration (FDA) approved esketamine (Spravato) last spring for treating depression that is resistant to traditional treatments.
Journal of Addictions Nursing
October 1, 2019
William J Lorman
Treatment resistant depression is a common and burdensome condition with poor outcomes and few treatment options. Approximately one third of patients with major depressive disorder are treatment resistant to the current antidepressants. In addition, depression in patients with bipolar disorder is typically poorly responsive to antidepressants. And so, there is an unmet need for rapidly acting...
Pharmaceuticals
September 11, 2019
Brittany O’brien, Marijn Lijffijt, Allison Wells et al.
Childhood maltreatment is associated with a poor treatment response to conventional antidepressants and increased risk for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor (NDMAR) antagonist ketamine has been shown to rapidly improve symptoms of depression in patients with TRD. It is unknown if childhood maltreatment could influence ketamine’s treatment response. We...